Erytech Pharma SA Performance
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Erytech Pharma are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Erytech Pharma SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Erytech Pharma is not utilizing all of its potentials. The newest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 33.7 M |
Erytech |
Erytech Pharma Relative Risk vs. Return Landscape
If you would invest (100.00) in Erytech Pharma SA on December 22, 2024 and sell it today you would earn a total of 100.00 from holding Erytech Pharma SA or generate -100.0% return on investment over 90 days. Erytech Pharma SA is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Erytech, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Erytech Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Erytech Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Erytech Pharma SA, and traders can use it to determine the average amount a Erytech Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ERYP |
Based on monthly moving average Erytech Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Erytech Pharma by adding Erytech Pharma to a well-diversified portfolio.
Erytech Pharma Fundamentals Growth
Erytech Stock prices reflect investors' perceptions of the future prospects and financial health of Erytech Pharma, and Erytech Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Erytech Stock performance.
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (4.08) % | |||
| Current Valuation | 211.16 K | |||
| Shares Outstanding | 34.12 M | |||
| Price To Earning | (5.88) X | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 7.58 X | |||
| EBITDA | (22.69 M) | |||
| Cash And Equivalents | 54.05 M | |||
| Cash Per Share | 1.74 X | |||
| Total Debt | 13.57 M | |||
| Debt To Equity | 1.00 % | |||
| Book Value Per Share | 0.76 X | |||
| Cash Flow From Operations | (31.76 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 45.81 M | |||
| Retained Earnings | (228 K) | |||
| Current Asset | 94.53 M | |||
| Current Liabilities | 9.8 M | |||
Things to note about Erytech Pharma SA performance evaluation
Checking the ongoing alerts about Erytech Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Erytech Pharma SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Erytech Pharma SA is not yet fully synchronised with the market data | |
| Erytech Pharma SA has some characteristics of a very speculative penny stock | |
| Erytech Pharma SA has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (228 K) with profit before overhead, payroll, taxes, and interest of 4.18 M. | |
| Erytech Pharma SA currently holds about 54.05 M in cash with (31.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. |
- Analyzing Erytech Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Erytech Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Erytech Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Erytech Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Erytech Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Erytech Pharma's stock. These opinions can provide insight into Erytech Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |